SCHEMBL1188345

SCHEMBL1188345

CCOc1ccc(F)cc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.56
HSD17B10 Q99714 1/20 0.56
MRGPRX1 Q96LB2 4/20 0.50
KMT2A Q03164 2/20 0.50
LMNA P02545 1/20 0.50
PKM P14618 1/20 0.49
KEAP1 Q14145 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.47
GAA P10253 1/20 0.47
GLA P06280 1/20 0.46
TSPO P30536 1/20 0.45
HCRTR1 O43613 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.44
S1PR3 Q99500 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31078354 1.00 TSHR (0.56) TSHRHSD17B10MRGPRX1KMT2ALMNA
SCHEMBL4600863 0.87 PTPN11 (0.56) TSHRHSD17B10KMT2ALMNA
SCHEMBL7959141 0.87 PTPN11 (0.51) HSD17B10KMT2APKMKEAP1MEN1
SCHEMBL15048810 0.86 TSHR (0.51) TSHRHSD17B10MRGPRX1KMT2ALMNA
SCHEMBL3165420 0.86 CYP3A4 (0.61) TSHRMRGPRX1LMNAL3MBTL1TSPO
SCHEMBL30628345 0.86 CYP3A4 (0.61) TSHRMRGPRX1LMNAL3MBTL1TSPO
SCHEMBL5023065 0.85 MRGPRX1 (0.47) TSHRHSD17B10MRGPRX1PKML3MBTL1
SCHEMBL31565683 0.85 MAPK1 (0.50) TSHRHSD17B10MRGPRX1KMT2ALMNA
SCHEMBL11287767 0.85 MRGPRX1 (0.49) TSHRHSD17B10MRGPRX1L3MBTL1GLA
SCHEMBL19320833 0.84 TTR (0.60) TSHRHSD17B10KMT2ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630541-B2 Compounds useful as inhibitors of ALCAT 1 PERENNA PHARMACEUTICALS, INC. (US) 2026-05-19 US disclosed
CN-120136858-A Compounds useful as ALCAT1 inhibitors 中美博瑞纳制药有限公司 2025-06-13 CN disclosed
CN-110709394-B Compounds useful as ALCAT1 inhibitors 中美博瑞纳制药有限公司 2025-02-21 CN disclosed
US-20220089582-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 PERENNA PHARMACEUTICALS, INC. 2022-03-24 US disclosed
US-11208404-B2 Compounds useful as inhibitors of ALCAT 1 PERENNA PHARMACEUTICALS, INC. (US) 2021-12-28 US disclosed
US-20200109136-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 PERENNA PHARMACEUTICALS, INC. 2020-04-09 US disclosed
EP-3601274-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 Perenna Pharmaceuticals, Inc. (US) 2020-02-05 EP disclosed
CN-110709394-A Compounds useful as ALCAT1 inhibitors 中美博瑞纳制药有限公司 2020-01-17 CN disclosed
WO-2018178304-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 PERENNA PHARMACEUTICALS, INC. (US) 2018-10-04 WO disclosed
EP-2794608-B1 TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS MERCK PATENT GMBH (DE) 2016-09-14 EP disclosed
EP-2794608-A1 TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS Merck Patent GmbH (DE) 2014-10-29 EP disclosed
US-8735425-B2 Tetrahydroisoquinoline derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-27 US disclosed
EP-2674434-A1 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators ARES TRADING S.A. (CH) 2013-12-18 EP disclosed
EP-2256105-B1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-12-04 EP disclosed
WO-2013091773-A1 TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS MERCK PATENT GMBH (DE) 2013-06-27 WO disclosed
EP-2607364-A1 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators Ares Trading S.A. (CH) 2013-06-26 EP disclosed
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-10 US disclosed
EP-2256105-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-12-01 EP disclosed
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089582-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 ACAT1, ACAT2, SLC33A1 TSHR 3322/4885HSD17B10 178/4885MRGPRX1 2957/4885
US-12630541-B2 Compounds useful as inhibitors of ALCAT 1 LCLAT1, LPCAT1, ACAT2 TSHR 3727/4885HSD17B10 609/4885MRGPRX1 2991/4885
US-11208404-B2 Compounds useful as inhibitors of ALCAT 1 ACAT1, ACAT2, SLC33A1 TSHR 3322/4885HSD17B10 178/4885MRGPRX1 2957/4885
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DGAT1, DGAT2, DLAT TSHR 1378/4885HSD17B10 462/4885MRGPRX1 69/4885
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 TSHR 1728/4885HSD17B10 854/4885MRGPRX1 1380/4885
US-20200109136-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 ACAT1, ACAT2, SLC33A1 TSHR 3322/4885HSD17B10 178/4885MRGPRX1 2957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.